Karo Bio AB Receives Funding From the National MS Society to Develop ERbeta Agonists for Treatment of Progressive Multiple Sclerosis

Published: Sep 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karo Bio AB (STO:KARO) has been awarded $0,5 million from the National Multiple Sclerosis Society through Fast Forward to develop a novel treatment – ERbeta agonists -- for progressive forms of Multiple Sclerosis (MS). The funds will finance the further preclinical development of Karo Bio’s advanced compounds. Karo Bio’s ERbeta agonist has the potential to slow disease progression in multiple sclerosis as preclinical models show that it protects neurons and restores myelin. Damaged myelin leads to symptoms of illness and disability in MS patients. This intended profile differs dramatically from currently approved MS therapies, which are used for the treatment of relapsing MS and reduce inflammation, but do not restore myelin or directly protect neurons.

Help employers find you! Check out all the jobs and post your resume.

Back to news